Marshall Wace, LLP Neu Base Therapeutics, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $130,806 - $210,295	-50,310 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $281,582 - $409,888	-86,111 Reduced 63.12%	50,310 $182,000
Q2 2021 Aug 13, 2021	BUY	$4.63 - $7.34 $631,629 - $1 Million	136,421 New	136,421 $653,000
Q3 2020 Nov 16, 2020	SELL	$7.25 - $9.71 $98,832 - $132,366	-13,632 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$6.69 - $11.51 $91,198 - $156,904	13,632 New	13,632 $120,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.